药物相关的快速眼动睡眠行为障碍研究新进展

doi:10.12114/j.issn.1007-9572.2024.0347

摘要/Abstract

摘要： 快速眼动睡眠行为障碍（RBD）是一种异态睡眠，主要表现为快速眼动（REM）期出现肌张力失弛缓和梦境演绎行为，常对患者及其床伴的生活质量造成严重影响。根据是否存在明确的RBD诱发因素，可将其分为特发性RBD和继发性RBD，后者常与发作性睡病、自身免疫性和炎性疾病及药物使用有关。近年来已经陆续有病例报道抗抑郁药、抗精神病药及少数其他药物可诱发或加重药物相关的RBD。本文主要对药物相关的RBD进行系统回顾，并总结其病理机制及治疗方法。

关键词: REM睡眠行为障碍, 药物, 快速眼球运动睡眠, 综述

Abstract:

Rapid eye movement sleep behavior disorder (RBD) is a parasomnia characterized by the loss of muscle atonia and the enactment of dreams during REM sleep, which can significantly impact the quality of life for both patients and their bed partners. RBD can be classified into two types based on the presence or absence of clear precipitating factors: idiopathic rapid eye movement sleep behavior disorder (iRBD) and secondary rapid eye movement sleep behavior disorder (sRBD). sRBD is often associated with conditions such as narcolepsy, autoimmune and inflammatory diseases, and medication use. In recent years, there have been reports of drug-related RBD, particularly associated with antidepressants, antipsychotics, and other medications. This article provided a systematic review of drug-related RBD, summarized its pathological mechanisms and treatment approaches.

Key words: REM sleep behavior disorder, Drug, REM sleep, Review

中图分类号:

R 749.79

王怡,程金湘,赵显超,等. 药物相关的快速眼动睡眠行为障碍研究新进展[J]. 中国全科医学, 2025, 28(35): 4511-4516. DOI: 10.12114/j.issn.1007-9572.2024.0347.
WANG Yi,CHENG Jinxiang,ZHAO Xianchao, et al. Research Progress on Drug-related Rapid Eye Movement Sleep Behavior Disorder[J]. Chinese General Practice, 2025, 28(35): 4511-4516. DOI: 10.12114/j.issn.1007-9572.2024.0347.

参考文献 54

[1]	SOBREIRA-NETO M A, STELZER F G, GITAÍ L L G, et al. REM sleep behavior disorder：update on diagnosis and management[J]. Arq Neuropsiquiatr，2023，81（12）：1179-1194. DOI：10.1055/s-0043-1777111.
[2]	POSTUMA R B, IRANZO A, HU M, et al. Risk and predictors of dementia and Parkinsonism in idiopathic REM sleep behaviour disorder：a multicentre study[J]. Brain，2019，142（3）：744-759. DOI：10.1093/brain/awz030.
[3]	LU J, XU X F, HUANG Y Q, et al. Prevalence of depressive disorders and treatment in China：a cross-sectional epidemiological study[J]. Lancet Psychiatry，2021，8（11）：981-990. DOI：10.1016/S2215-0366(21)00251-0.
[4]	HABA-RUBIO J, FRAUSCHER B, MARQUES-VIDAL P, et al. Prevalence and determinants of rapid eye movement sleep behavior disorder in the general population[J]. Sleep，2018，41（2）：zsx197. DOI：10.1093/sleep/zsx197.
[5]	MCCARLEY R W, HOBSON J A. Neuronal excitability modulation over the sleep cycle：a structural and mathematical model[J]. Science，1975，189（4196）：58-60. DOI：10.1126/science.1135627.
[6]	HOLST S C, LANDOLT H P. Sleep-wake neurochemistry[J]. Sleep Med Clin，2022，17（2）：151-160. DOI：10.1016/j.jsmc.2022.03.002.
[7]	GOTT J A, STÜCKER S, KANSKE P, et al. Acetylcholine and metacognition during sleep[J]. Conscious Cogn，2024，117：103608. DOI：10.1016/j.concog.2023.103608.
[8]	FRAIGNE J J, TORONTALI Z A, SNOW M B, et al. REM sleep at its core - circuits，neurotransmitters，and pathophysiology[J]. Front Neurol，2015，6：123. DOI：10.3389/fneur.2015.00123.
[9]	SHEN C C, TSAI S J, PERNG C L, et al. Risk of parkinson disease after depression：a nationwide population-based study[J]. Neurology，2013，81（17）：1538-1544. DOI：10.1212/WNL.0b013e3182a956ad.
[10]	KIM H J, KIM S J, LEE S A. Severity of idiopathic rapid eye movement sleep behavior disorder correlates with depression and alexithymia[J]. Sleep Med，2020，74：25-30. DOI：10.1016/j.sleep.2020.05.039.
[11]	WANG J, CHAU S W H, LAM S P, et al. Prevalence and correlates of REM sleep behaviour disorder in patients with major depressive disorder：a two-phase study[J]. J Neurol Neurosurg Psychiatry，2022，93（9）：1010-1017. DOI：10.1136/jnnp-2021-327460.
[12]	POSTUMA R B, GAGNON J F, TUINEAIG M, et al. Antidepressants and REM sleep behavior disorder：isolated side effect or neurodegenerative signal?[J]. Sleep，2013，36（11）：1579-1585. DOI：10.5665/sleep.3102.
[13]	LOCHMANN D, RICHARDSON T. Selective serotonin reuptake inhibitors[J]. Handb Exp Pharmacol，2019，250：135-144. DOI：10.1007/164_2018_172.
[14]	SCHENCK C H, MAHOWALD M W, KIM S W, et al. Prominent eye movements during NREM sleep and REM sleep behavior disorder associated with fluoxetine treatment of depression and obsessive-compulsive disorder[J]. Sleep，1992，15（3）：226-235. DOI：10.1093/sleep/15.3.226.
[15]	APPLEBEE G A, ATTARIAN H P, SCHENCK C H. An angry bed partner[J]. JCSM，2009，5（5）：477-479.
[16]	PARISH J M. Violent dreaming and antidepressant drugs：or how paroxetine made me dream that I was fighting saddam hussein[J]. J Clin Sleep Med，2007，3（5）：529-531. DOI：10.5664/jcsm.26919.
[17]	SHEYNER I, KHAN S, STEWART J T. A case of selective serotonin reuptake inhibitor-induced rapid eye movement behavior disorder[J]. J Am Geriatr Soc，2010，58（7）：1421-1422. DOI：10.1111/j.1532-5415.2010.02947.x.
[18]	ZHANG B, HAO Y L, JIA F J, et al. Sertraline and rapid eye movement sleep without atonia：an 8-week，open-label study of depressed patients[J]. Prog Neuropsychopharmacol Biol Psychiatry，2013，47：85-92. DOI：10.1016/j.pnpbp.2013.08.010.
[19]	DU Y L, JIANG J J, NG C H, et al. Vortioxetine improves rapid eye movement sleep behavior disorder：a case report[J]. Medicine，2020，99（26）：e21003. DOI：10.1097/MD.0000000000021003.
[20]	TAKAHASHI T, MITSUYA H, MURATA T, et al. Opposite effects of SSRIs and tandospirone in the treatment of REM sleep behavior disorder[J]. Sleep Med，2008，9（3）：317-319. DOI：10.1016/j.sleep.2007.05.003.
[21]	HOPKINS S C, DEDIC N, KOBLAN K S. Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans[J]. Transl Psychiatry，2021，11（1）：228. DOI：10.1038/s41398-021-01331-9.
[22]	BONILLA-JAIME H, SÁNCHEZ-SALCEDO J A, ESTEVEZ-CABRERA M M, et al. Depression and pain：use of antidepressants[J]. Curr Neuropharmacol，2022，20（2）：384-402. DOI：10.2174/1570159X19666210609161447.
[23]	TAN L, ZHOU J Y, YANG L H, et al. Duloxetine-induced rapid eye movement sleep behavior disorder：a case report[J]. BMC Psychiatry，2017，17（1）：372. DOI：10.1186/s12888-017-1535-4.
[24]	KLUGE M, SCHÜSSLER P, STEIGER A. Duloxetine increases stage 3 sleep and suppresses rapid eye movement（REM）sleep in patients with major depression[J]. Eur Neuropsychopharmacol，2007，17（8）：527-531. DOI：10.1016/j.euroneuro.2007.01.006.
[25]	RYAN WILLIAMS R, SANDIGO G. Venlafaxine-induced REM sleep behavioral disorder presenting as two fractures[J]. Trauma Case Rep，2017，11：18-19. DOI：10.1016/j.tcr.2017.10.017.
[26]	LEE K, BARON K, SOCA R, et al. The prevalence and characteristics of REM sleep without Atonia（RSWA）in patients taking antidepressants[J]. J Clin Sleep Med，2016，12（3）：351-355. DOI：10.5664/jcsm.5582.
[27]	WATANABE K. Antidepressants[J]. Brain and Nerve，2023，75（5）：573-578. DOI：10.11477/mf.1416202381.
[28]	HISHIKAWA Y, IDA H, NAKAI K, et al. Treatment of narcolepsy with imipramine（tofranil）and desmethylimipramine（pertofran）[J]. J Neurol Sci，1966，3（5）：453-461. DOI：10.1016/0022-510x(66)90001-3.
[29]	ROTH B, FABER J, NEVSÍMALOVÁ S, et al. The influence of imipramine，dexphenmetrazine and amphetaminsulphate upon the clinical and polygraphic picture of narcolepsy-cataplexy[J]. Schweiz Arch Neurol Neurochir Psychiatr，1971，108（2）：251-260.
[30]	ATTARIAN H P, SCHENCK C H, MAHOWALD M W. Presumed REM sleep behavior disorder arising from cataplexy and wakeful dreaming[J]. Sleep Med，2000，1（2）：131-133. DOI：10.1016/s1389-9457(99)00013-1.
[31]	GUILLEMINAULT C, RAYNAL D, TAKAHASHI S, et al. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride[J]. Acta Neurol Scand，1976，54（1）：71-87. DOI：10.1111/j.1600-0404.1976.tb07621.x.
[32]	ARNULF I. REM sleep behavior disorder：motor manifestations and pathophysiology[J]. Mov Disord，2012，27（6）：677-689. DOI：10.1002/mds.24957.
[33]	NAOI M, MARUYAMA W, SHAMOTO-NAGAI M. Neuroprotective function of rasagiline and selegiline，inhibitors of type B monoamine oxidase，and role of monoamine oxidases in synucleinopathies[J]. Int J Mol Sci，2022，23（19）：11059. DOI：10.3390/ijms231911059.
[34]	AKINDELE M O, EVANS J I, OSWALD I. Mono-amine oxidase inhibitors，sleep and mood[J]. Electroencephalogr Clin Neurophysiol，1970，29（1）：47-56. DOI：10.1016/0013-4694(70)90078-7.
[35]	LOUDEN M B, MOREHEAD M A, SCHMIDT H S. Activation by selegiline（Eldepryle）of REM sleep behavior disorder in Parkinsonism[J]. W V Med J，1995，91（3）：101.
[36]	BISCARINI F, PIZZA F, VANDI S, et al. Biomarkers of neurodegeneration in isolated and antidepressant-related rapid eye movement sleep behavior disorder[J]. Eur J Neurol，2024，31（6）：e16260. DOI：10.1111/ene.16260.
[37]	GRINCHII D, DREMENCOV E. Mechanism of action of atypical antipsychotic drugs in mood disorders[J]. Int J Mol Sci，2020，21（24）：9532. DOI：10.3390/ijms21249532.
[38]	TAN L, ZHOU J Y, LIANG B, et al. A case of quetiapine-induced rapid eye movement sleep behavior disorder[J]. Biol Psychiatry，2016，79（5）：e11-12. DOI：10.1016/j.biopsych.2014.08.002.
[39]	ZHAO H X, LI S, WANG Y M. A case report of atypical sleep in an ischemic stroke patient with psychiatric symptoms caused by olanzapine[J]. Front Neurol，2023，14：1266204. DOI：10.3389/fneur.2023.1266204.
[40]	CHOW R T S, WHITING D, FAVRIL L, et al. An umbrella review of adverse effects associated with antipsychotic medications：the need for complementary study designs[J]. Neurosci Biobehav Rev，2023，155：105454. DOI：10.1016/j.neubiorev.2023.105454.
[41]	KURIYAMA S. Bisoprolol-induced nightmares[J]. J Hum Hypertens，1994，8（9）：730.
[42]	WESTERLUND A. Central nervous system side-effects with hydrophilic and lipophilic beta-blockers[J]. Eur J Clin Pharmacol，1985，28 Suppl：73-76. DOI：10.1007/BF00543714.
[43]	IRANZO A, SANTAMARIA J. Bisoprolol-induced rapid eye movement sleep behavior disorder[J]. Am J Med，1999，107（4）：390-392. DOI：10.1016/s0002-9343(99)00245-4.
[44]	SIGAROUDI A, KINZIG M, WAHL O, et al. Quantification of bisoprolol and metoprolol in simultaneous human serum and cerebrospinal fluid samples[J]. Pharmacology，2018，101（1/2）：29-34. DOI：10.1159/000480091.
[45]	UCHIYAMA M, ISSE K, TANAKA K, et al. Incidental Lewy body disease in a patient with REM sleep behavior disorder[J]. Neurology，1995，45（4）：709-712. DOI：10.1212/wnl.45.4.709.
[46]	ROSS J S, SHUA-HAIM J R. Aricept-induced nightmares in Alzheimer's disease：2 case reports[J]. J Am Geriatr Soc，1998，46（1）：119-120. DOI：10.1111/j.1532-5415.1998.tb01033.x.
[47]	YEH S B, YEH P Y, SCHENCK C H. Rivastigmine-induced REM sleep behavior disorder（RBD）in a 88-year-old man with Alzheimer's disease[J]. J Clin Sleep Med，2010，6（2）：192-195.
[48]	RINGMAN J M, SIMMONS J H. Treatment of REM sleep behavior disorder with donepezil：a report of three cases[J]. Neurology，2000，55（6）：870-871. DOI：10.1212/wnl.55.6.870.
[49]	DI GIACOPO R, FASANO A, QUARANTA D, et al. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson's disease[J]. Mov Disord，2012，27（4）：559-561. DOI：10.1002/mds.24909.
[50]	STAER K, IRANZO A, TERKELSEN M H, et al. Progression of brain cholinergic dysfunction in patients with isolated rapid eye movement sleep behavior disorder[J]. Eur J Neurol，2024，31（1）：e16101. DOI：10.1111/ene.16101.
[51]	HOWELL M, AVIDAN A Y, FOLDVARY-SCHAEFER N, et al. Management of REM sleep behavior disorder：an American academy of sleep medicine systematic review，meta-analysis，and GRADE assessment[J]. J Clin Sleep Med，2023，19（4）：769-810. DOI：10.5664/jcsm.10426.
[52]	MOGHADAM K K, PIZZA F, PRIMAVERA A, et al. Sodium oxybate for idiopathic REM sleep behavior disorder：a report on two patients[J]. Sleep Med，2017，32：16-21. DOI：10.1016/j.sleep.2016.04.014.
[53]	SASAI T, INOUE Y, MATSUURA M. Effectiveness of pramipexole，a dopamine agonist，on rapid eye movement sleep behavior disorder[J]. Tohoku J Exp Med，2012，226（3）：177-181. DOI：10.1620/tjem.226.177.
[54]	CHICA-URZOLA H L. Trazodone in REM sleep behavior disorder[J]. Rev Colomb Psiquiatr，2015，44（4）：251-255. DOI：10.1016/j.rcp.2015.04.004.